Acadia Pharmaceuticals appoints Jonathan M. Poole to board and Audit Committee
Acadia Pharmaceuticals appointed Jonathan M. Poole as a director on March 3, 2026, filling a board vacancy, and named him to the Audit Committee effective immediately. The filing details his director pay and an initial equity grant with a target value of $200,000, plus a prorated annual grant of $95,300, which adds to the board's composition and compensation terms but does not report any financial results.
Key points
- Poole appointed to the Board on March 3, 2026 as a Class II director, with a term expiring at the 2027 Annual Meeting of Stockholders
- Annual cash retainers of $50,000 for board service and $12,500 for Audit Committee membership, prorated per the Policy
- Initial equity grant with target fair value of $200,000 and prorated annual grant with target fair value of $95,300, both vesting over one year to three years
- Future annual equity grant target value of $400,000 starting with the 2026 Annual Meeting of Stockholders
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.